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Opinion
Guillain-Barré syndrome (GBS) is an immune-mediated periph-
eral neuropathy, with an annual incidence of approximately 1–2 
cases per 100,000 persons.1–3 The most common symptom of GBS 
is a rapidly evolving, ascending weakness, with mild sensory loss 
and hyporeflexia or areflexia progressing to a nadir over up to 4 
weeks.2,3 GBS is considered to be an autoimmune disease with 
involvement of both cellular and humoral immune responses,2 but 
about a quarter of the patients with GBS have suffered a recent 
bacterial or viral infection, and axonal forms of the disease are es-
pecially common in these patients.2,4–9 Pathogens such as Campy-
lobacter jejuni, Haemophilus bacteria and Cytomegalovirus have 
been shown to have oligosaccharide structures [Gal beta 1-3 Gal-
NAc beta 1-4 (NeuAc alpha 2-3) Gal beta] in their lipopolysac-
charide coat responsible for the molecular mimicry that triggers 
GBS.2,5,7,10–13 In addition, different types of viral diseases, such as 
hepatitis caused by hepatitis C virus, acquired immune deficiency 
syndrome caused by the human immunodeficiency virus and dis-
ease caused by the mosquito-borne Zika virus, have been related 
to GBS.8,9 Additionally, rare cases of GBS have been reported after 
treatment with inactivated influenza vaccine.14 Recent results have 
shown that infection with these pathogens leads to anti-GM1 pen-
tasaccharide beta-Gal-(1-3)-beta-GalNAc-(1-4)-[alpha-Neu5Ac-
(2-3)]-beta-Gal-(1-4)-beta-Glc antibody production, which cross-
reacts with gangliosides and other glycolipids, leading to myelin 
destruction by complement activation or by antibodies targeting 
macrophages via the Fc receptor and leading to both demyelina-
tion and nerve conduction failure.2,4,15
Alpha-Gal syndrome (AGS) is a tick-induced allergy trig-
gered by IgE antibody response against the carbohydrate Galα1-
3Galβ1-(3)4GlcNAc-R (α-Gal), which is present in glycoproteins 
from tick saliva and tissues of noncatarrhine mammals.16,17 AGS 
is characterized by delayed anaphylaxis to red meat consumption 
and certain drugs, such as cetuximab, and immediate anaphylaxis 
to tick bites, and is becoming a global problem with increasing 
prevalence in all continents and with the involvement of several 
tick species.16–20 Humans do not produce the carbohydrate α-Gal 
(Gal α 1-3Gal β 1-(3)4GlcNAc-R),21 and the not yet fully un-
derstood immune response induced by tick bites that includes 
anti-α-Gal IgE antibodies break the oral tolerance to food aller-
gens, resulting in a gut-related but not lung-related allergy.16,20 
The GGTA1 gene encoding for the α1,3-galactosyltransferase 
enzyme that synthetizes α-Gal in mammals was inactivated in 
humans, apes and Old World monkeys approximately 28 million 
years ago.21 This resulted in an almost unique capacity of these 
animals to produce high levels of anti-α-Gal antibodies. Several 
pathogens, such as Leishmania, Trypanosoma, Plasmodium and 
Mycobacterium, have been found to produce α-Gal on their sur-
face, and infection with some of these pathogens induces an anti-
α-Gal response.22,23 Anti-α-Gal antibodies can also be produced 
in response to bacterial microbiota,21 and they constitute the most 
abundant antibody in humans, representing about 1% of total im-
munoglobulins.21
Anti-α-Gal IgG and IgM antibodies induced by bacterial mi-
crobiota were shown to control malaria transmission by comple-
ment-mediated lysis.22 The proposed mechanisms triggering AGS 
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involve Toll-like receptor-mediated responses in both Th1 and Th2 
cells, with a role for basophils in this process.16 Therefore, GGTA1 
gene inactivation might have occurred in response to the selection 
pressure exerted by pathogens detrimental to primates that produce 
α-Gal.21 Consequently, the capacity of the human immune system 
to respond to pathogens producing α-Gal evolved with the tradeoff 
of AGS.17,24
These results suggested that both GBS and AGS are related to 
infectious diseases and driven by immune response to galactose-
containing oligosaccharide structures. Humans produce GM1 
and the anti-GM1 antibodies induced by pathogen infection 
break the tolerance to the self-antigen GM1, leading to myelin 
destruction and GBS. However, humans do not produce α-Gal 
and anti-α-Gal IgE antibodies induced by tick bites result in 
anaphylactic reaction to the consumption of red meat contain-
ing this carbohydrate and leading to the AGS. Interestingly, both 
diseases overcome the immune tolerance ‘easily’, a mechanism 
otherwise known to be quite robust for other antigens, such as 
cancer-related antigens.25 However, differences between the two 
diseases are also important to consider for the development of 
proper interventions.26
The carbohydrate epitopes involved in GBS are very complex, 
including a range of gangliosides, such as GM2, GM1, GM1b, 
GD1a, GalNAc-Gd1a and GQ1b, that beside galactose involve 
other monosaccharides, including NeuNAc (5-N-acetylneuramin-
ic acid) and GalNAc (2-N-acetyl-galactosamine). The NeuNAc is 
found in most epitopes of GBS, playing the most important role 
in the immunochemistry of GBS carbohydrate epitopes. However, 
the galactosyl oligosaccharide residue plays an essential role in 
AGS. Pathomechanistically, GBS is the result of the body’s adap-
tive immune response to foreign antigens, which have structures 
similar to human gangliosides that generate antibodies acciden-
tally recognizing human gangliosides and resulting in autoimmune 
reactions. On the other hand, AGS is an allergic reaction triggered 
by tick bites and after eating red meat containing the α-Gal trisac-
charide, which is a hyper-reaction of human immune systems to 
foreign antigens.16
What we can learn from these findings? Besides differences 
in the carbohydrate epitopes playing the main role in GBS and 
AGS and other pathomechanistic differences, the immunological 
basis of GBS and AGS have some similarities (Fig. 1). Trying to 
understand how immunity is regulated in response to galactose-
containing oligosaccharides and other carbohydrate structures 
produced by pathogens and ticks that result in GBS or AGS is 
essential to prevent these diseases.15–17 Recent results from our 
group showed that application of the latest postgenomic or omics 
technologies would facilitate the characterization of the immune 
response in both GBS and AGS, with the possible identification of 
target molecules for diagnostics, treatment and prevention of these 
diseases.27–30
In summary, deciphering the immune-mediated mechanisms in-
volved in GBS and AGS would lead to new diagnostic, treatment 
and prevention/control interventions for these diseases, and have 
possible implications for the control of major infectious diseases.31
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